|
Mutation Information
|
Mutation Site
|
T215F |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Relevant Drug
|
NRTIs |
|
Country
|
China |
Literature Information
|
PubMed PMID
|
33252379
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2020 |
|
Journal
|
Chinese medical journal |
|
Title
|
Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study. |
|
Author
|
Su B,Yao C,Zhao QX,Cai WP,Wang M,Lu HZ,Chen YY,Liu L,Wang H,He Y,Zheng YH,Li LH,Chen JF,Yu JH,Zhu B,Zhao M,Sun YT,Lun WH,Xia W,Sun LJ,Dai LL,Jiang TY,Wang MX,Zheng QS,Peng HY,Wang Y,Lu RJ,Hu JH,Xing H,Shao YM,Xie D,Zhang T,Zhang FJ,Wu H,TALENT Study Team. |
|
Evidence
|
NRTI resistance mutations (M41L and T215F) that had emerged since baseline were noted in one patient from the ABT group, whereas the M184V, M41LM, and K70KR mutations were observed in three patients from the NRTI group.
|
|
|
HIV Mutation Detail Information